Who Buys Pyrantel from India — 127 Importers Behind a $3.3M Market

The importation of Pyrantel from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like HINCUS PHARMACEUTICALS (Russia) and GLADPHARM LTD. (Ukraine) function as intermediaries, procuring large quantities to supply to pharmacies, hospitals, and clinics. Their bulk purchasing often leads to economies of scale, and they typically place regular, sizable orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as AO NPC ELFA (Russia) and JAMP PHARMA CORPORATION (Canada) import Pyrantel as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is aligned with production schedules, resulting in periodic, large-volume purchases.

• Government Procurement Agencies: Entities like REGENCY PHARMA LIMITED (Mauritius) and SANTEVIE SARL (Congo) may engage in tender-based purchasing to supply public health programs. Their buying patterns are influenced by government budgets and public health initiatives, often leading to bulk orders during specific procurement cycles.

• Retail Chains and Hospital Groups: While not explicitly listed among the top buyers, these entities typically procure Pyrantel to meet patient demand, resulting in smaller, more frequent orders compared to distributors or government agencies.

• Re-exporters: Some buyers may act as re-exporters, purchasing Pyrantel for distribution to neighboring countries, thereby extending the reach of Indian exports beyond direct importers.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and purchasing behaviors of each group.

Russia

1. Drug Regulatory Authority: Ministry of Health of the Russian Federation.

2. Import Registration Process for Pyrantel: Requires submission of a registration dossier, including clinical data, quality control documentation, and labeling information.

3. Estimated Timeline for Registration: Approximately 12-18 months, depending on the completeness of the application and any additional requirements.

4. Import Tariff/Duty for HS 30049021: Typically ranges from 5% to 10%, subject to changes based on trade agreements and economic policies.

Ukraine

1. Drug Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control.

2. Import Registration Process for Pyrantel: Involves submission of an application with comprehensive product information, including manufacturing details and clinical efficacy data.

3. Estimated Timeline for Registration: Approximately 12 months, contingent upon the review process and any required inspections.

4. Import Tariff/Duty for HS 30049021: Generally around 5%, but may vary based on specific trade agreements.

Canada

1. Drug Regulatory Authority: Health Canada.

2. Import Registration Process for Pyrantel: Requires filing a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) for generic products, including detailed scientific and clinical data.

3. Estimated Timeline for Registration: Typically 12-24 months, depending on the complexity of the submission and review process.

4. Import Tariff/Duty for HS 30049021: Pharmaceutical products are generally duty-free under the Most Favored Nation (MFN) tariff treatment.

Mauritius

1. Drug Regulatory Authority: Pharmacy Board of Mauritius.

2. Import Registration Process for Pyrantel: Involves submission of an application with product specifications, manufacturing details, and evidence of registration in the country of origin.

3. Estimated Timeline for Registration: Approximately 6-12 months, subject to the evaluation process and any additional requirements.

4. Import Tariff/Duty for HS 30049021: Generally exempt from import duties, but subject to a Value Added Tax (VAT) of around 15%.

Congo

1. Drug Regulatory Authority: Ministry of Health and Population.

2. Import Registration Process for Pyrantel: Requires submission of a registration dossier, including product information, quality control data, and proof of registration in the country of origin.

3. Estimated Timeline for Registration: Approximately 12-18 months, depending on the review process and any required inspections.

4. Import Tariff/Duty for HS 30049021: Typically around 5%, but may vary based on specific trade agreements and economic policies.

The demand for Pyrantel in importing countries is primarily driven by the prevalence of soil-transmitted helminth infections, such as ascariasis, whipworm, and hookworm. These parasitic infections are common in regions with inadequate sanitation and are a significant public health concern. Pyrantel is recognized for its efficacy in treating these conditions, making it a critical component in national deworming programs and mass drug administration campaigns. For instance, the World Health Organization (WHO) includes Pyrantel in its Model List of Essential Medicines, underscoring its importance in addressing helminth infections. (who.int)

Government healthcare initiatives and the expansion of universal health coverage further bolster the demand for Pyrantel. Many countries have integrated deworming treatments into their public health strategies, often procuring medications through tender-based purchasing to ensure cost-effectiveness and widespread distribution. The inclusion of Pyrantel in the WHO Essential Medicines List facilitates its procurement by international organizations and national health programs, enhancing accessibility and affordability. With 127 buyers across 54 countries, the market for Pyrantel demonstrates a broad and sustained demand, presenting significant opportunities for suppliers to meet global health needs.

The importation of Pyrantel from India involves various buyer segments, each with distinct purchasing behaviors:

• Distributors: Entities like HINCUS PHARMACEUTICALS (Russia) and GLADPHARM LTD. (Ukraine) function as intermediaries, procuring large quantities to supply to pharmacies, hospitals, and clinics. Their bulk purchasing often leads to economies of scale, and they typically place regular, sizable orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as AO NPC ELFA (Russia) and JAMP PHARMA CORPORATION (Canada) import Pyrantel as an active pharmaceutical ingredient (API) for formulation into finished products. Their procurement is aligned with production schedules, resulting in periodic, large-volume purchases.

• Government Procurement Agencies: Entities like REGENCY PHARMA LIMITED (Mauritius) and SANTEVIE SARL (Congo) may engage in tender-based purchasing to supply public health programs. Their buying patterns are influenced by government budgets and public health initiatives, often leading to bulk orders during specific procurement cycles.

• Retail Chains and Hospital Groups: While not explicitly listed among the top buyers, these entities typically procure Pyrantel to meet patient demand, resulting in smaller, more frequent orders compared to distributors or government agencies.

• Re-exporters: Some buyers may act as re-exporters, purchasing Pyrantel for distribution to neighboring countries, thereby extending the reach of Indian exports beyond direct importers.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and purchasing behaviors of each group.

Russia

1. Drug Regulatory Authority: Ministry of Health of the Russian Federation.

2. Import Registration Process for Pyrantel: Requires submission of a registration dossier, including clinical data, quality control documentation, and labeling information.

3. Estimated Timeline for Registration: Approximately 12-18 months, depending on the completeness of the application and any additional requirements.

4. Import Tariff/Duty for HS 30049021: Typically ranges from 5% to 10%, subject to changes based on trade agreements and economic policies.

Ukraine

1. Drug Regulatory Authority: State Service of Ukraine on Medicines and Drugs Control.

2. Import Registration Process for Pyrantel: Involves submission of an application with comprehensive product information, including manufacturing details and clinical efficacy data.

3. Estimated Timeline for Registration: Approximately 12 months, contingent upon the review process and any required inspections.

4. Import Tariff/Duty for HS 30049021: Generally around 5%, but may vary based on specific trade agreements.

Canada

1. Drug Regulatory Authority: Health Canada.

2. Import Registration Process for Pyrantel: Requires filing a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) for generic products, including detailed scientific and clinical data.

3. Estimated Timeline for Registration: Typically 12-24 months, depending on the complexity of the submission and review process.

4. Import Tariff/Duty for HS 30049021: Pharmaceutical products are generally duty-free under the Most Favored Nation (MFN) tariff treatment.

Mauritius

1. Drug Regulatory Authority: Pharmacy Board of Mauritius.

2. Import Registration Process for Pyrantel: Involves submission of an application with product specifications, manufacturing details, and evidence of registration in the country of origin.

3. Estimated Timeline for Registration: Approximately 6-12 months, subject to the evaluation process and any additional requirements.

4. Import Tariff/Duty for HS 30049021: Generally exempt from import duties, but subject to a Value Added Tax (VAT) of around 15%.

Congo

1. Drug Regulatory Authority: Ministry of Health and Population.

2. Import Registration Process for Pyrantel: Requires submission of a registration dossier, including product information, quality control data, and proof of registration in the country of origin.

3. Estimated Timeline for Registration: Approximately 12-18 months, depending on the review process and any required inspections.

4. Import Tariff/Duty for HS 30049021: Typically around 5%, but may vary based on specific trade agreements and economic policies.

The demand for Pyrantel in importing countries is primarily driven by the prevalence of soil-transmitted helminth infections, such as ascariasis, whipworm, and hookworm. These parasitic infections are common in regions with inadequate sanitation and are a significant public health concern. Pyrantel is recognized for its efficacy in treating these conditions, making it a critical component in national deworming programs and mass drug administration campaigns. For instance, the World Health Organization (WHO) includes Pyrantel in its Model List of Essential Medicines, underscoring its importance in addressing helminth infections. (who.int)

Government healthcare initiatives and the expansion of universal health coverage further bolster the demand for Pyrantel. Many countries have integrated deworming treatments into their public health strategies, often procuring medications through tender-based purchasing to ensure cost-effectiveness and widespread distribution. The inclusion of Pyrantel in the WHO Essential Medicines List facilitates its procurement by international organizations and national health programs, enhancing accessibility and affordability. With 127 buyers across 54 countries, the market for Pyrantel demonstrates a broad and sustained demand, presenting significant opportunities for suppliers to meet global health needs.